Innate Pharma Announces Strategic Partnership with Sobi and Clinical Progress in Q2 Earnings Call
Innate Pharma (NASDAQ:IPHA) announced key developments during its second-quarter earnings call, including a strategic partnership with Sobi for lacutamab. The deal includes an upfront payment of $75 million from Sobi and €30 million raised through equity financing, extending the company's cash runway to Q1 2028. Lacutamab has received multiple regulatory designations in both the U.S. and Europe and is now entering its phase III TELLOMAK-3 trial for cutaneous T-cell lymphoma. The company also highlighted progress on monalizumab's PACIFIC-9 phase III study, with results expected by mid-year 2026, as well as initial data from IPH4502, an antibody-drug conjugate showing early responses in solid tumors. Innate plans to seek accelerated approval for lacutamab in Sézary syndrome during the second half of 2027 and anticipates potential inclusion in NCCN guidelines following regulatory clearance. The partnership with Sobi grants exclusive global commercialization rights if lacutamab receives accelerated approval, while positive phase III results could transfer full development rights to Sobi. Pricing research suggests annual treatment costs between €500,000 and €625,000 per patient in the U.S., supported by clinical data.
Topics: biotech clinical trials partnerships pharmaceuticals